FDA Expands Approval of Omnipod 5 Insulin Delivery System to Include Patients With Type 2 Diabetes
By Physician’s Briefing Staff HealthDay Reporter
TUESDAY, Aug. 27, 2024 -- On Monday, the U.S. Food and Drug Administration approved the Insulet Omnipod 5 insulin delivery system for patients with type 2 diabetes. It is the first such system for use by people with the more prevalent form of the disease.
The FDA first signed off on the system, which automatically adjusts insulin delivery as needed, for type 1 diabetes in 2022. In approving Insulet's Omnipod 5 insulin delivery system for type 2 diabetes patients, the FDA said the clearance "provides a new option that can automate many of these manual tasks [of tracking and managing blood glucose levels], potentially reducing the burden of living with this chronic disease."
"The FDA has long worked with the diabetes community to ensure access to additional options and flexibilities for diabetes management," Michelle Tarver, M.D., acting director of the FDA Center for Devices and Radiological Health, said in a news release announcing the expanded use. "The FDA is committed to advancing new device innovation that can improve the health and quality of life for people living with chronic diseases that require day-to-day maintenance like diabetes."
Insulet applauded the expanded approval.
"Today's announcement represents a significant milestone in providing easy-to-use, patient-centric technology for the treatment of type 2 diabetes," Insulet CEO Jim Hollingshead said in a company news release.
With the new system, the wearable product provides up to three days of nonstop insulin delivery without the need to handle a needle. The Omnipod 5 works in concert with a continuous glucose monitor to manage blood glucose with no daily injections and no finger pricks.
In approving the expanded use, the FDA reviewed data from a clinical study of 289 individuals 18 years and older with type 2 diabetes for 13 weeks. Volunteers' blood glucose control improved, and these improvements were seen across all demographic groups. Adverse events were generally mild to moderate and included hyperglycemia, hypoglycemia, and skin irritation.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2024
Read this next
Semaglutide May Lower Risk for Opioid Overdose in T2DM, Opioid Use Disorder
WEDNESDAY, Sept. 25, 2024 -- For patients with type 2 diabetes (T2D) and opioid use disorder (OUD), semaglutide is associated with a significantly lower risk for opioid overdose...
Exposure to Toxic Metals Linked to Faster Increases in Glycemia
MONDAY, Sept. 23, 2024 -- Exposure to toxic metals and alterations in essential metal homeostasis are associated with faster increases in glycemia over time in a high-risk Mexican...
Metformin Use Tied to Lower Incidence of Death, Long COVID After COVID-19
THURSDAY, Sept. 19, 2024 -- After severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, prevalent metformin use is associated with a slightly lower incidence of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.